二吲哚甲烷 Diindolylmethane (DIM) × 更年期

結論:台灣市場資訊黑箱

獨立判讀為 U(未驗證):DIM × 更年期目前在文獻上不存在任何測量更年期症狀(熱潮紅、盜汗、睡眠、情緒、GSM、QoL)的 RCT 或系統性回顧,全部 5 篇人體研究只測尿液雌激素代謝物比例(2-OHE1/16α-OHE1),且族群是 BRCA 帶因者、tamoxifen 治療中的乳癌存活者、或使用 transdermal estradiol 貼片的停經後婦女——不是有症狀的更年期患者;代謝物比例位移是 biomarker 假說,未經驗證為更年期症狀改善的 surrogate。

U ⚫ U 未驗證 台灣法規禁言 ⚠️ medium — moderate promotional content
⚠️ 標記 💊 檢驗 / 藥物交互作用

獨立判讀為 U(未驗證):DIM × 更年期目前在文獻上不存在任何測量更年期症狀(熱潮紅、盜汗、睡眠、情緒、GSM、QoL)的 RCT 或系統性回顧,全部 5 篇人體研究只測尿液雌激素代謝物比例(2-OHE1/16α-OHE1),且族群是 BRCA 帶因者、tamoxifen 治療中的乳癌存活者、或使用 transdermal estradiol 貼片的停經後婦女——不是有症狀的更年期患者;代謝物比例位移是 biomarker 假說,未經驗證為更年期症狀改善的 surrogate。

NAMS 2023(Levels I-II)、ACOG PB-141(Level A)、Endocrine Society 2015 三大學會以 umbrella 否定所有 OTC 補充品用於 VMS,且 PMID 40298801(2025 Menopause 期刊)顯示 DIM 反而會將 transdermal estradiol 偏轉至 2-hydroxylation 路徑、降低 HRT 有效雌激素活性,意味 DIM 在 HRT 使用者身上可能反向加重更年期症狀。

雖然 Health Canada NNHPD 核可 60-200 mg/d 並核可「support healthy estrogen metabolism/balance」聲明,但同一專論明確要求『若出現熱潮紅、夜間盜汗、陰道乾澀等低雌激素症狀者使用前須諮詢醫師』——等於把更年期症狀本身列為使用前警示,而非適應症。

整體屬於『無症狀端點人體證據 + 學會 umbrella 否定 + 機轉與 HRT 反向 + 多項主要藥物交互作用』的組合,比起 D(有反證據)更接近 U(未驗證),但實質效益面接近 D 級的『不建議』方向。

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.39
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
U · 台灣法規禁言
信心度
85%
證據方向一致性高
證據層級
E6
多篇較小型隨機對照試驗

各層「支持此療效」的程度

分數越低=該層越不支持
L11 AI 複核獨立判讀
0.20
L5 臨床機構權威立場
0.31
L2 PubMed原始文獻
0.40
L1 Examine國際基準
0.50
L3 機轉生理合理性
0.50
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.393
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — D 級條件未達 (需 E1-E3 negative;實際 E6)
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

The impact of 3,3'-diindolylmethane on estradiol and estrogen metabolism in postmenopausal women using a transdermal estradiol patch
PMID: 40298801 2025 Cohort n = 1,458
結論:DIM users showed statistically significant alterations across 7 of 10 urinary estrogen metabolites vs non-users (multivariable regression P=0.002-0.02; overall profile P<0.001) — lower estrone/estriol, higher 2-hydroxyestrone and 2-hydroxyestradiol; suggests DIM shifts patch-delivered estradiol toward 2-hydroxylation pathway
⚠️ 廠商資助
前往 PubMed
Exploring the impact of 3,3'-diindolylmethane on the urinary estrogen profile of premenopausal women
PMID: 39578798 2024 Cohort n = 19,294
結論:DIM users had significantly different concentrations in almost every urinary estrogen metabolite vs non-users (p<0.001 for all except 2-methoxyestrone); 2-OHE1:16-OHE1 ratio increased significantly in before/after analysis (p<0.001)
🟠 品質有限 ⚠️ 廠商資助
前往 PubMed
3,3-Diindolylmethane (DIM): a nutritional intervention and its impact on breast density in healthy BRCA carriers. A prospective clinical trial
PMID: 32458980 2020 RCT (open-label) n = 23
結論:FGT decreased 2.8 to 2.65 (P=0.031); estradiol decreased 159 to 102 pmol/L (P=0.01); testosterone decreased 0.42 to 0.31 pmol/L (P=0.007). Median age 47y, 78% postmenopausal but not stratified
🟠 品質有限 效應量:[object Object]
前往 PubMed
The effect of oral 3,3'-diindolylmethane supplementation on the 2:16alpha-OHE ratio in BRCA1 mutation carriers
PMID: 25613194 2015 RCT (open-label) n = 20
結論:Ratio increased from 2.4 to 3.0 but NOT statistically significant (P=0.35); authors concluded short DIM intervention did not significantly raise the 2:16 ratio. Menopausal status not specified
🟠 品質有限 效應量:[object Object]
前往 PubMed
Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer
PMID: 15623462 2004 RCT (double-blind) n = 19
結論:DIM significantly increased urinary 2-OHE1 (P=0.020) and 2:16-alpha-OHE1 ratio vs placebo; small pilot, NOT measuring menopause symptoms — relevant only as estrogen-metabolism mechanism evidence, in tamoxifen-treated breast cancer survivors
🟠 品質有限 學術資助
前往 PubMed

L4a US FDA
謹慎
3,3'-DIINDOLYLMETHANE 來源↗
L4b EU EFSA
反對
Purified, synthetic 3,3'-diindolylmethane powder in supplement form is considered novel... 3,3'-diindolylmethane powder has been classified as a 'Novel Food' because it had not been consumed to a significant degree by humans in the UK or the European Union before May 15, 1997. It has not been granted authorization for sale as a food supplement. 來源↗
L4c UK NHS
未表態
— 本適應症無對應資料
L4d TW TFDA / 衛福部
未表態
— 本適應症無對應資料
L4e WHO
支持
3,3'-Diindolylmethane (DIM). CAS 1968-05-4. Source materials: Brassica oleracea var. botrytis (cauliflower), var. capitata (cabbage), var. gemmifera (Brussels sprouts), var. italica (broccoli) — whole plant. Schedule 1, Item 2 (isolate). Approved Use(s) or Purpose(s): Source of/Provides antioxidants that help fight/protect cells against/reduce the oxidative effects of (or oxidative damage cause… 來源↗

L5a NIH Office of Dietary Supplements
謹慎
L5b Mayo Clinic
中性
— 本適應症無對應資料
L5c Cleveland Clinic
未表態
— 本適應症無對應資料
L5d Harvard Health
未表態
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
反對

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 中度
📍立場總覽

PTT(regimen/WomenTalk/BeautySalon)、Dcard、Mobile01、痞客邦皆查無「二吲哚甲烷/DIM」針對更年期的真實鄉民實測討論。台灣更年期社群主要討論大豆異黃酮,而非 DIM;DIM 在台灣多以雌激素優勢、痘痘、經前症候群脈絡出現,且現有中文內容幾乎都是部落格/電商業配(GK健康網、姬菈原生、營養新知、Amazon、iHerb),非匿名社群辯證。依規範不杜撰社群討論。

💬社群實感

無共識(台灣社群幾乎無針對更年期的 DIM 實測心得)

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

DIM,二吲哚甲烷,100毫克,120片

代表來源 ↗
L10b · TFDA 法定身份 官方認定

尚未獲得台灣TFDA核准作為任何疾病之治療藥物

來源 ↗

  • 停經期荷爾蒙治療(MHT)
  • 陰道局部雌激素(治療泌尿生殖症候群)
  • 生活型態調整(規律運動、體重管理、戒菸)
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 5 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v6 engine_version: v1.0 claim_id: CLM-COND-menopause-INT-diindolylmethane-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-menopause-INT-diindolylmethane-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "二吲哚甲烷能改善更年期",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "alternateName": "證據不足 (Insufficient evidence)"
  }
}